Relation Between Dietary Fat Intake Type and Serum Fatty Acid Status in Children with Cystic Fibrosis

Overview

Journal J Pediatr Gastroenterol Nutr

Publisher Wiley

Date 2012 Jun 16

PMID 22699835

Citations 17

Authors

Asim Maqbool

Joan I Schall

Paul R Gallagher

Babette S Zemel

Birgitta Strandvik

Virginia A Stallings

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Children with cystic fibrosis (CF) and pancreatic insufficiency (PI) are at risk for fatty acid (FA) abnormalities and essential FA deficiency, with low linoleic acid (LA) and docosahexaenoic acid (DHA) concentrations and abnormal triene:tetraene (T:T) and arachidonic acid (AA):DHA ratios. The aim of the article was to determine whether type of dietary fat predicted serum LA, DHA, T:T, and AA:DHA ratios in subjects with CF and PI as compared to an unaffected comparison group.

Methods: Serum FA concentrations were assessed by capillary gas-liquid chromatography (mol%) and dietary intake by 7-day weighed food records; the 3-day coefficient of fat absorption was calculated. Total energy intake was expressed in kilocalories.

Results: A total of 65 subjects with CF and PI (8.4 ± 1.0 years, 32 girls) and 22 controls (8.5 ± 1.1 years, 13 girls) were included. Despite greater energy, saturated fat, and LA intake, the subjects with CF had lower serum LA and DHA and higher T:T and AA:DHA than those in the comparison group. Dietary total fat, monounsaturated fatty acid (MUFA), polyunsaturated fatty acid (PUFA), LA, total ω 6 polyunsaturated fatty acid (Tω6PUFA), and α-linolenic acid (ALA) intake positively predicted serum LA concentration. MUFA, total ω 3 polyunsaturated fatty acid (Tω3PUFA), and ALA intake positively predicted serum DHA concentration. Total dietary fat, MUFA, PUFA, Tω3PUFA, LA, and ALA intake negatively predicted serum T:T. ALA and Tω3PUFA intake negatively predicted serum AA:DHA.

Conclusions: Dietary fat patterns influenced serum LA, DHA, T:T, and AA:DHA in children with CF and PI. These data suggest that changes in dietary practices may result in FA profiles associated with improved clinical outcomes.

Citing Articles

Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?.

Drzymala-Czyz S, Walkowiak J, Colombo C, Alicandro G, Storrosten O, Kolsgaard M iScience. 2024; 27(11):111153.

PMID: 39620135 PMC: 11607544. DOI: 10.1016/j.isci.2024.111153.

Dietary intake assessment in children with cystic fibrosis using 3-day food diaries: a single-centre study.

Gaschignard M, Beaufils F, Gallet P, Clouzeau H, Menard J, Costanzo A Front Pediatr. 2023; 11:1130792.

PMID: 37228437 PMC: 10203471. DOI: 10.3389/fped.2023.1130792.

Validation of an omega-3 substrate challenge absorption test as an indicator of global fat lipolysis.

Freedman S, Zaworski K, Pierzynowska K, Pierzynowski S, Gallotto R, Sathe M PLoS One. 2023; 18(5):e0284651.

PMID: 37155649 PMC: 10166528. DOI: 10.1371/journal.pone.0284651.

Essential Fatty Acid Deficiency in Cystic Fibrosis Disease Progression: Role of Genotype and Sex.

Shrestha N, McCarron A, Rout-Pitt N, Donnelley M, Parsons D, Hryciw D Nutrients. 2022; 14(21).

PMID: 36364928 PMC: 9657825. DOI: 10.3390/nu14214666.

Utilization of the Healthy Eating Index in Cystic Fibrosis.

Bass R, Tindall A, Sheikh S Nutrients. 2022; 14(4).

PMID: 35215485 PMC: 8875613. DOI: 10.3390/nu14040834.

References

Coste T, Armand M, Lebacq J, Lebecque P, Wallemacq P, Leal T . An overview of monitoring and supplementation of omega 3 fatty acids in cystic fibrosis. Clin Biochem. 2007; 40(8):511-20. DOI: 10.1016/j.clinbiochem.2007.01.002. View

Panchaud A, Sauty A, Kernen Y, Decosterd L, Buclin T, Boulat O . Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial. Clin Nutr. 2005; 25(3):418-27. DOI: 10.1016/j.clnu.2005.10.011. View

Savitz D, Olshan A . Multiple comparisons and related issues in the interpretation of epidemiologic data. Am J Epidemiol. 1995; 142(9):904-8. DOI: 10.1093/oxfordjournals.aje.a117737. View

Gronowitz E, Mellstrom D, Strandvik B . Serum phospholipid fatty acid pattern is associated with bone mineral density in children, but not adults, with cystic fibrosis. Br J Nutr. 2006; 95(6):1159-65. DOI: 10.1079/bjn20061778. View

Trabulsi J, Ittenbach R, Schall J, Olsen I, Yudkoff M, Daikhin Y . Evaluation of formulas for calculating total energy requirements of preadolescent children with cystic fibrosis. Am J Clin Nutr. 2007; 85(1):144-51. DOI: 10.1093/ajcn/85.1.144. View

Maqbool A, Schall J, Garcia-Espana J, Zemel B, Strandvik B, Stallings V . Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2008; 47(5):635-44. PMC: 4482449. DOI: 10.1097/MPG.0b013e31817fb76b. View

Folch J, Lees M, SLOANE STANLEY G . A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226(1):497-509. View

Plourde M, Cunnane S . Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab. 2007; 32(4):619-34. DOI: 10.1139/H07-034. View

Walkowiak J, Lisowska A, Blaszczynski M, Przyslawski J, Walczak M . Polyunsaturated fatty acids in cystic fibrosis are related to nutrition and clinical expression of the disease. J Pediatr Gastroenterol Nutr. 2007; 45(4):488-9. DOI: 10.1097/MPG.0b013e3180690da9. View

10.

LLOYD-STILL J, Bibus D, Powers C, Johnson S, Holman R . Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatr. 1996; 85(12):1426-32. DOI: 10.1111/j.1651-2227.1996.tb13947.x. View

11.

Van Biervliet S, Devos M, Delhaye T, Van Biervliet J, Robberecht E, Christophe A . Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients. Prostaglandins Leukot Essent Fatty Acids. 2008; 78(2):109-15. DOI: 10.1016/j.plefa.2007.12.005. View

12.

Lloyd-Still J, Powers C, Hoffman D, Boyd-Trull K, Lester L, Benisek D . Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition. 2005; 22(1):36-46. DOI: 10.1016/j.nut.2005.05.006. View

13.

Strandvik B . Relation between essential fatty acid metabolism and gastrointestinal symptoms in cystic fibrosis. Acta Paediatr Scand Suppl. 1989; 363:58-63; discussion 63-5. DOI: 10.1111/apa.1989.78.s363.58. View

14.

Holman R . The ratio of trienoic: tetraenoic acids in tissue lipids as a measure of essential fatty acid requirement. J Nutr. 1960; 70(3):405-10. DOI: 10.1093/jn/70.3.405. View

15.

Jumpsen J, Brown N, Thomson A, Paul Man S, Goh Y, Ma D . Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J Cyst Fibros. 2006; 5(2):77-84. DOI: 10.1016/j.jcf.2006.01.004. View

16.

Stubbs C, Smith A . The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim Biophys Acta. 1984; 779(1):89-137. DOI: 10.1016/0304-4157(84)90005-4. View

17.

Borowitz D, Baker R, Stallings V . Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr. 2002; 35(3):246-59. DOI: 10.1097/00005176-200209000-00004. View

18.

Brenna J, Salem Jr N, Sinclair A, Cunnane S . alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fatty Acids. 2009; 80(2-3):85-91. DOI: 10.1016/j.plefa.2009.01.004. View

19.

Cawood A, Carroll M, Wootton S, Calder P . Is there a case for n-3 fatty acid supplementation in cystic fibrosis?. Curr Opin Clin Nutr Metab Care. 2005; 8(2):153-9. DOI: 10.1097/00075197-200503000-00008. View

20.

Olveira G, Olveira C, Acosta E, Espildora F, Garrido-Sanchez L, Garcia-Escobar E . Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Arch Bronconeumol. 2010; 46(2):70-7. DOI: 10.1016/j.arbres.2009.11.001. View